Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 5/20 | 0.41 |
| ▸ | NTMT1 | Q9BV86 | 2/20 | 0.40 |
| ▸ | GRB2 | P62993 | 1/20 | 0.39 |
| ▸ | F2 | P00734 | 4/20 | 0.39 |
| ▸ | PLG | P00747 | 1/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15524993 | 1.00 | DPP4 (0.41) | DPP4NTMT1GRB2F2PLG | |
| SCHEMBL9577364 | 1.00 | DPP4 (0.41) | DPP4NTMT1GRB2F2PLG | |
| SCHEMBL31124688 | 0.96 | OPRM1 (0.41) | NTMT1GRB2F2OPRM1OPRK1 | |
| SCHEMBL31437198 | 0.93 | NTMT1 (0.41) | DPP4NTMT1F2OPRM1OPRK1 | |
| SCHEMBL29569634 | 0.92 | NTMT1 (0.47) | NTMT1GRB2F2OPRM1OPRK1 | |
| SCHEMBL29886815 | 0.91 | DPP4 (0.42) | DPP4NTMT1GRB2F2PLG | |
| SCHEMBL30452201 | 0.91 | NRP1 (0.43) | GRB2OPRM1OPRK1 | |
| SCHEMBL29556306 | 0.91 | BDKRB2 (0.39) | DPP4OPRM1 | |
| SCHEMBL5863304 | 0.91 | EPHA2 (0.41) | DPP4NTMT1OPRM1OPRK1 | |
| SCHEMBL31124690 | 0.91 | OPRM1 (0.43) | OPRM1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 96 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117551176-B | Efficient preparation method of triptorelin acetate | 鲁南新时代生物技术有限公司 | 2025-05-27 | — | — | CN | claimed |
| CN-118684727-A | GPRP series peptide modified dabigatran derivative, synthesis, activity and application thereof | 首都医科大学 | 2024-09-24 | — | — | CN | claimed |
| CN-117551176-A | Efficient preparation method of triptorelin acetate | 山东新时代药业有限公司 | 2024-02-13 | — | — | CN | claimed |
| US-11718687-B2 | Biomoletron for regulation stem cell differentiation | SOGANGN UNIVERSITY RESEARCH FOUNDATION (KR) | 2023-08-08 | — | — | US | claimed |
| CN-113929739-B | Gly-Pro-Arg-Pro-NH ethoxycarbonyl warfarin, synthesis, activity and application thereof | 首都医科大学 | 2023-07-28 | — | — | CN | claimed |
| EP-3955003-B1 | SENSORS FOR ASSAYING COAGULATION IN FLUID SAMPLES | ABBOTT POINT OF CARE INC (US) | 2023-06-21 | — | — | EP | claimed |
| EP-3198281-B1 | ELLAGIC ACID FORMULATIONS FOR USE IN COAGULATION ASSAYS | ABBOTT POINT OF CARE INC (US) | 2023-01-25 | — | — | EP | claimed |
| CN-109111502-B | 1, 1-dihydroxymethyl-tetrahydro-beta-carboline-3-formyl-GGPRP, and synthesis, activity and application thereof | 首都医科大学 | 2022-04-22 | — | — | CN | claimed |
| EP-3955003-A1 | SENSORS FOR ASSAYING COAGULATION IN FLUID SAMPLES | Abbott Point Of Care Inc (US) | 2022-02-16 | — | — | EP | claimed |
| WO-2001005948-A1 | ASSAY OF THE ACTIVATION STATE OF PLATELETS | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 2001-01-25 | — | — | WO | claimed |
| US-3966701-A | ANTICOAGULANTS | THE DOW CHEMICAL COMPANY (US) | 1976-06-29 | — | — | US | claimed |
| JP-5320114-A | — | — | None | — | — | JP | disclosed |
| EP-4743102-A1 | COLLAGEN PEPTIDE COMPOSITION AND USE THEREOF IN AMELIORATING NEUROLOGICAL CONDITIONS AND FIBROSIS | Rousselot BV (BE) | 2026-05-20 | — | — | EP | disclosed |
| WO-2026087731-A1 | PHARMACEUTICAL COMPOSITION COMPRISING AN AMINO ACID COMPOSITION IN PURIFIED HYALURONIC ACID | INTIBIO BV (BE) | 2026-04-30 | — | — | WO | disclosed |
| US-12606797-B2 | Methods of detection of mechanically-activated platelet activation and uses thereof | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2026-04-21 | — | — | US | disclosed |
| EP-3955003-A1 | SENSORS FOR ASSAYING COAGULATION IN FLUID SAMPLES | Abbott Point Of Care Inc (US) | 2022-02-16 | — | — | EP | disclosed |
| JP-H05320114-A | METHOD FOR DISSOLVING P-NITROANILIDE DERIVATIVE | WAKO PURE CHEM IND LTD | 1993-12-03 | — | — | JP | disclosed |
| US-4070245-A | Substrate for the quantitative determination of proteolytic enzymes | PENTAPHARM A.G. (CH) | 1978-01-24 | — | — | US | disclosed |
| US-3966701-A | ANTICOAGULANTS | THE DOW CHEMICAL COMPANY (US) | 1976-06-29 | — | — | US | disclosed |
| US-3966701-A | ANTICOAGULANTS | THE DOW CHEMICAL COMPANY (US) | 1976-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12606797-B2 | Methods of detection of mechanically-activated platelet activation and uses thereof | GP6, F13B, SELPLG | DPP4 3477/4885NTMT1 4661/4885GRB2 446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.